Today's Trend
Pulse Biosciences, Inc. (PLSE) — Shares are trading lower after the company reported mixed Q4/2025 results and several corporate developments. Investors are reacting to a modest EPS beat but a revenue miss, notable insider stock sales, and routine corporate filings (inducement awards and conference scheduling) that together appear to have weighed on sentiment despite positive clinical updates. Volume is elevated, suggesting active repositioning.
- Q4 EPS beat analyst expectations — Pulse reported a loss of $0.26 per share vs. consensus -$0.32, beating estimates and showing a smaller-than-expected loss. This helped limit downside after the print. Article
- Clinical/business update: company highlighted strong procedural results for its endocardial nPulse catheter (100% freedom from AF at 6 months, 96% procedural success), supporting long‑term product potential and commercialization story. Article
- Investor outreach: Pulse will present at the 46th Annual TD Cowen Healthcare Conference — useful for visibility and investor Q&A but not an immediate revenue driver. Article
- Inducement equity grants: the board awarded equity inducements to two new employees under Nasdaq Rule 5635(c)(4). Standard hiring practice; could be seen as modestly dilutive over time but routine. Article
- Revenue missed expectations — reported revenue was effectively flat/negative ($-0.09M) vs. the consensus ~$0.23M, raising near-term commercialization and cash‑flow concerns for some investors. Press release / results
- Insider selling: recent filings show insiders sold roughly $0.94M combined in two transactions, which investors may interpret as a negative signal on near‑term insider conviction. Sale 1 Sale 2
Bottom line for investors: the EPS beat and positive procedural data are constructive for the long‑term story, but the revenue shortfall and insider sales appear to be driving short‑term selling pressure. Watch upcoming conference presentation, management commentary in the earnings call transcript, and any guidance or cash‑runway details for near‑term direction. Relevant transcripts and the company release are available for deeper review.